Versantis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://versantis.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
- Conditions
- Hepatic EncephalopathyAcute on Chronic Liver Failure (ACLF)Decompensated Cirrhosis
- Interventions
- Drug: VS-01 on top of SOC (Active Treatment Group)Drug: SOC
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Versantis AG
- Target Recruit Count
- 3
- Registration Number
- NCT06987968
- Locations
- 🇺🇸
96 Jonathan Lucas St, CSB (Main Hospital), Suite 908, Charleston, South Carolina, United States
🇫🇷Nouvel Hôpital Civil, Service de Medecine Intensive Reanimation, 1, place de l'Hôpital, Strasbourg, France
🇬🇪Georgian Clinics" Kutaisi Referral Hospital 2, Otskheli str., Kutaisi, Georgia
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
- Conditions
- AscitesAcute-On-Chronic Liver Failure
- Interventions
- Drug: VS-01 on top of SOCOther: SOC (Control Group)
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-10-29
- Lead Sponsor
- Versantis AG
- Target Recruit Count
- 15
- Registration Number
- NCT05900050
- Locations
- 🇺🇸
University of California Davis Medical Center, Sacramento, California, United States
🇺🇸Medstar Georgetown University Hospital, Washington D.C., District of Columbia, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
News
Liver Cirrhosis Pipeline Shows Strong Growth with 30+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ liver cirrhosis therapies, with promising candidates like Rezdiffra, efruxifermin, and belapectin showing significant clinical progress.